Protein Biomarkers and Host RNA Expression Profiles in Congenital Cytomegalovirus Infection
NCT07635368 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 630
Last updated 2026-06-09
Summary
This study seeks to identify and test host protein biomarkers and RNA expression profiles in dried blood spot samples as novel diagnostic markers of congenital cytomegalovirus sequelae and to improve the understanding of the pathogenesis of the disease.
Conditions
- Congenital Cytomegalovirus
- Cytomegalovirus Infections
- Neonatal Infection
- Sensorineural Hearing Loss
- Viral Infection
Sponsors & Collaborators
-
Statens Serum Institut
collaborator OTHER -
Rigshospitalet, Denmark
lead OTHER
Principal Investigators
-
Kia Hee Schultz Dungu, MD · Rigshospitalet, Denmark
-
Ulrikka Nygaard, Ass Prof PhD · Rigshospitalet, Denmark
Eligibility
- Min Age
- 0 Days
- Max Age
- 28 Days
- Sex
- ALL
- Healthy Volunteers
- Yes
Timeline & Regulatory
- Start
- 2026-04-21
- Primary Completion
- 2026-09-30
- Completion
- 2026-12-31
Countries
- Denmark
Study Locations
More Related Trials
-
Safety, Tolerability, and Immunogenicity of a Cytomegalovirus DNA Vaccine
NCT02594566 ·Status: WITHDRAWN ·Phase: PHASE1
-
Cytomegalovirus (CMV) Infection in Pregnancy
NCT00194155 ·Status: COMPLETED
-
Immune Response and Cytomegalovirus in Intensive Care Unit (ICU) Patients
NCT00699868 ·Status: COMPLETED ·Phase: NA
-
Evaluation of the Safety and Immune Responses of the Towne Strain of CMV in Seronegative Women
NCT00201448 ·Status: TERMINATED ·Phase: PHASE2/PHASE3
-
Study to Evaluate Safety and Immunogenicity of the GSK Bio CMV Vaccine in CMV-seronegative Healthy Male Adult Subjects
NCT00435396 ·Status: COMPLETED ·Phase: PHASE1
-
Study of the Transmission of Cytomegalovirus (CMV) Infection From Mother to Foetus
NCT01251744 ·Status: COMPLETED ·Phase: NA
-
Detection of Cytomegalovirus Virus in Neonates
NCT03251261 ·Status: COMPLETED
-
Safety, Tolerability, and Immunogenicity of the Human Cytomegalovirus Vaccine (V160) in Healthy Adults (V160-001)
NCT01986010 ·Status: COMPLETED ·Phase: PHASE1
-
Effect of Burn Size on Cytomegalovirus Reactivation and Correlates of T Cell Immune Function in Burned Patients
NCT00467532 ·Status: COMPLETED
-
CMV CTLs in Neonates With CMV Infection
NCT05564598 ·Status: RECRUITING ·Phase: PHASE2
-
A Randomized Trial to Prevent Congenital Cytomegalovirus (CMV)
NCT01376778 ·Status: COMPLETED ·Phase: PHASE3
-
TT-CMV Observational Birth Cohort Study
NCT00907686 ·Status: COMPLETED
-
Prevention of Maternal-fetal Cytomegalovirus Transmission After Primary Maternal Infection, GW ≤ 14 (PreCyssion)
NCT05170269 ·Status: TERMINATED ·Phase: PHASE3
-
CMV-specific Donor-derived T Lymphocytes for the Treatment of Recalcitrant CMV Infection in a Patient With Primary Immunodeficiency
NCT07015801 ·Status: ACTIVE_NOT_RECRUITING ·Phase: NA
-
A Study on Cytomegalovirus (CMV) Infection Outcomes Among Hematopoietic Stem Cell Transplant (HSCT) Participants in Europe and Canada
NCT05571137 ·Status: COMPLETED
-
The Maternal Cellular Immune System and Cytomegalovirus Intrauterine Infection
NCT01081379 ·Status: UNKNOWN
-
Vaccine Therapy in Preventing Cytomegalovirus in Healthy Participants
NCT00722839 ·Status: COMPLETED ·Phase: PHASE1
-
A Long-Term Extension Study to Evaluate the Immunogenicity and Safety of Cytomegalovirus (CMV) mRNA-1647 Vaccine
NCT04975893 ·Status: COMPLETED ·Phase: PHASE2
-
Cytomegalovirus Vaccine in Healthy Participants
NCT00712634 ·Status: COMPLETED ·Phase: PHASE1
-
Detection of Human Cytomegalovirus in the Saliva
NCT00815802 ·Status: COMPLETED
-
Clinical and Immunological Features of the CMV Infection Atypical Course in Immunocompetent Individuals
NCT04392297 ·Status: COMPLETED
-
Cytomegalovirus Cell-Mediated Immunity
NCT00815165 ·Status: COMPLETED
-
Cytomegalovirus (CMV) Transmission and Immune Tracking (TransmIT) Study
NCT06522880 ·Status: WITHDRAWN
-
Cytomegalovirus (CMV) Specific Cytotoxic T Lymphocytes (CTL) When Used for Prophylaxis Against CMV in Recipients of Allogeneic, T Cell Depleted Stem Cell Transplants
NCT00673868 ·Status: COMPLETED ·Phase: PHASE1
-
Non Primary HCMV Infection: Natural History and Immune Response
NCT06337955 ·Status: ACTIVE_NOT_RECRUITING